Copernicus Therapeutics

About:

Copernicus Therapeutics, Inc. (CTI) is a clinical stage biopharmaceutical company

Top Investors: Vivo Capital, Muzinich & Co, A. M. Pappas & Associates, GeneChem, Ohio Department of Development

Description:

Copernicus Therapeutics, Inc. (CTI) is a clinical stage biopharmaceutical company and a leader in the emerging field of precision medicine and gene therapy. Through their proprietary, non-viral, nucleic acid nanoparticle platform, they are able to achieve robust gene transfer in several tissues without the immune response and limited treatment window of AAV.

Total Funding Amount:

$6.6M

Estimated Revenue Range:

$1M to $10M

Headquarters Location:

Cleveland, Ohio, United States

Founded Date:

1995-01-01

Contact Email:

rmoen(AT)cgsys.com

Founders:

Thomas Ferkol

Number of Employees:

1-10

Last Funding Date:

2008-06-30

IPO Status:

Private

Industries: